{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T08:20:04Z","timestamp":1743063604894,"version":"3.35.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T00:00:00Z","timestamp":1219795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T00:00:00Z","timestamp":1219795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00228-008-0481-y","type":"journal-article","created":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T11:10:51Z","timestamp":1219749051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients"],"prefix":"10.1007","volume":"65","author":[{"given":"Doaa","family":"Elsherbiny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britt","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika S. H.","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,27]]},"reference":[{"issue":"4","key":"481_CR1","first-page":"550","volume":"121","author":"SK Sharma","year":"2005","unstructured":"Sharma SK, Mohan A, Kadhiravan T (2005) HIV-TB coinfection: epidemiology, diagnosis & management. Indian J Med Res 121(4):550\u2013567","journal-title":"Indian J Med Res"},{"issue":"9","key":"481_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","volume":"163","author":"EL Corbett","year":"2003","unstructured":"Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163(9):1009\u20131021","journal-title":"Arch Intern Med"},{"issue":"2","key":"481_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0009-9236(99)80079-4","volume":"65","author":"M Lamson","year":"1999","unstructured":"Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, Gigliotti M, Robinson P, Azzam S, Keirns J (1999) Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther 65(2):137","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"481_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14787210.2.3.367","volume":"2","author":"A Milinkovic","year":"2004","unstructured":"Milinkovic A, Martinez E (2004) Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2(3):367\u2013373","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"481_CR5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(24)12603-X","volume":"60","author":"B Goodwin","year":"2001","unstructured":"Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60(3):427\u2013431","journal-title":"Mol Pharmacol"},{"issue":"3","key":"481_CR6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","volume":"299","author":"JM Rae","year":"2001","unstructured":"Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299(3):849\u2013857","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"481_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/00003088-200342060-00009","volume":"42","author":"TE de Vries-Sluijs","year":"2003","unstructured":"de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME (2003) Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 42(6):599\u2013605","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"481_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1086\/514002","volume":"175","author":"MD de Jong","year":"1997","unstructured":"de Jong MD, Vella S, Carr A, Boucher CA, Imrie A, French M, Hoy J, Sorice S, Pauluzzi S, Chiodo F, Weverling GJ, van der Ende ME, Frissen PJ, Weigel HM, Kauffmann RH, Lange JM, Yoon R, Moroni M, Hoenderdos E, Leitz G, Cooper DA, Hall D, Reiss P (1997) High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 175(4):966\u2013970","journal-title":"J Infect Dis"},{"issue":"1","key":"481_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","volume":"42","author":"G Ramachandran","year":"2006","unstructured":"Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, Sathishnarayan S, Raja K, Kumaraswami V, Swaminathan S (2006) Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 42(1):36\u201341","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"481_CR10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","volume":"28","author":"E Ribera","year":"2001","unstructured":"Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, Ruiz I, Pahissa A (2001) Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 28(5):450\u2013453","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"481_CR11","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1097\/00002030-199912030-00029","volume":"13","author":"GL Dean","year":"1999","unstructured":"Dean GL, Back DJ, de Ruiter A (1999) Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 13(17):2489\u20132490","journal-title":"AIDS"},{"issue":"8","key":"481_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350501000809","volume":"10","author":"RS Autar","year":"2005","unstructured":"Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM (2005) Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 10(8):937\u2013943","journal-title":"Antivir Ther"},{"issue":"2","key":"481_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1086\/505210","volume":"43","author":"W Manosuthi","year":"2006","unstructured":"Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K (2006) Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 43(2):253\u2013255","journal-title":"Clin Infect Dis"},{"issue":"1","key":"481_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1086\/510078","volume":"44","author":"W Manosuthi","year":"2007","unstructured":"Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S (2007) Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 44(1):141\u2013144","journal-title":"Clin Infect Dis"},{"issue":"8","key":"481_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","volume":"27","author":"P Riska","year":"1999","unstructured":"Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27(8):895\u2013901","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"481_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tox.2004.12.019","volume":"209","author":"J Uetrecht","year":"2005","unstructured":"Uetrecht J (2005) Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. Toxicology 209(2):113\u2013118","journal-title":"Toxicology"},{"issue":"2","key":"481_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/dkm484","volume":"61","author":"K Cohen","year":"2008","unstructured":"Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G (2008) Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 61(2):389\u2013393","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"481_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0731-7085(02)00708-2","volume":"31","author":"J Chi","year":"2003","unstructured":"Chi J, Jayewardene AL, Stone JA, Aweeka FT (2003) An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal 31(5):953\u2013959","journal-title":"J Pharm Biomed Anal"},{"key":"481_CR19","volume-title":"NONMEM user\u2019s guide","author":"SL Beal","year":"1994","unstructured":"Beal SL, Sheiner LS (1994) NONMEM user\u2019s guide. NONMEM Project Group, University of California at San Fransisco, San Fransisco"},{"issue":"1","key":"481_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose- and S-PLUS-based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1):51\u201364","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"481_CR21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"EI Ette","year":"1997","unstructured":"Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37(6):486\u2013495","journal-title":"J Clin Pharmacol"},{"key":"481_CR22","unstructured":"HIVPharmcology (2006) Optimising TDM in HIV clinical care. Virology Education BV, Utrecht, the Netherlands. http:\/\/hivpharmacology.production.tdclighthouse.com\/content.cfm?lang=1&id=573&id2=639&ch=4&cid=639. Accessed 05 Nov 2007"},{"issue":"13","key":"481_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2165\/00003088-200443130-00002","volume":"43","author":"BS Kappelhoff","year":"2004","unstructured":"Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH (2004) Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 43(13):845\u2013853","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"481_CR24","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1208\/ps020101","volume":"2","author":"JP Sabo","year":"2000","unstructured":"Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR (2000) Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci 2(1):E1","journal-title":"AAPS PharmSci"},{"issue":"4","key":"481_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1046\/j.1365-2125.2002.01657.x","volume":"54","author":"MM de Maat","year":"2002","unstructured":"de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH (2002) Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 54(4):378\u2013385","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"481_CR26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.43.1.121","volume":"43","author":"XJ Zhou","year":"1999","unstructured":"Zhou XJ, Sheiner LB, D\u2019Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi JP (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 43(1):121\u2013128","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"481_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0168-3659(99)00034-6","volume":"62","author":"LZ Benet","year":"1999","unstructured":"Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62(1\u20132):25\u201331","journal-title":"J Control Release"},{"issue":"5","key":"481_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1124\/dmd.105.007559","volume":"34","author":"R Ohashi","year":"2006","unstructured":"Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I (2006) Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 34(5):793\u2013799","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"481_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clpt.2005.04.004","volume":"78","author":"LM Almond","year":"2005","unstructured":"Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH (2005) Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 78(2):132\u2013142","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"481_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1086\/507097","volume":"43","author":"DW Haas","year":"2006","unstructured":"Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB (2006) Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43(6):783\u2013786","journal-title":"Clin Infect Dis"},{"issue":"1","key":"481_CR31","first-page":"RA5","volume":"10","author":"J Sun","year":"2004","unstructured":"Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10(1):RA5\u2013RA14","journal-title":"Med Sci Monit"},{"issue":"8","key":"481_CR32","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","volume":"14","author":"RP van Heeswijk","year":"2000","unstructured":"van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14(8):F77\u201382","journal-title":"AIDS"},{"issue":"3","key":"481_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1021\/js970291i","volume":"87","author":"SL Glynn","year":"1998","unstructured":"Glynn SL, Yazdanian M (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 87(3):306\u2013310","journal-title":"J Pharm Sci"},{"issue":"8","key":"481_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1211\/0022357991773294","volume":"51","author":"B Lemmer","year":"1999","unstructured":"Lemmer B (1999) Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol 51(8):887\u2013890","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"481_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2174\/1389200043335450","volume":"5","author":"S Zhou","year":"2004","unstructured":"Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5(5):415\u2013442","journal-title":"Curr Drug Metab"},{"key":"481_CR36","unstructured":"Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH (2005) Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients (abstr 769). Available at http:\/\/www.page-meeting.org\/?abstract=769]"},{"key":"481_CR37","first-page":"S263","volume":"9","author":"SH Norris","year":"1992","unstructured":"Norris SH, Silverstein HH, St. George RL, Johnstone JN (1992) Nevirapine, an HIV-1 reverse transcriptase inhibitor: absorption, distribution and execretion in rats. Pharm Res 9:S263","journal-title":"Pharm Res"},{"issue":"2","key":"481_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.37.2.178","volume":"37","author":"SH Cheeseman","year":"1993","unstructured":"Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ (1993) Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 37(2):178\u2013182","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"481_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1099-081X(199909)20:6<285::AID-BDD187>3.0.CO;2-V","volume":"20","author":"MJ Lamson","year":"1999","unstructured":"Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 20(6):285\u2013291","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"481_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1515\/CCLM.2002.229","volume":"40","author":"J Salomon","year":"2002","unstructured":"Salomon J, de Truchis P, Melchior JC (2002) Body composition and nutritional parameters in HIV and AIDS patients. Clin Chem Lab Med 40(12):1329\u20131333","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"481_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1468-1293.2006.00391.x","volume":"7","author":"HO Olawumi","year":"2006","unstructured":"Olawumi HO, Olatunji PO (2006) The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV\/AIDS patients. HIV Med 7(6):351\u2013355","journal-title":"HIV Med"},{"issue":"5","key":"481_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2125.2006.02664.x","volume":"62","author":"N von Hentig","year":"2006","unstructured":"von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A (2006) A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 62(5):552\u2013559","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"481_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00228-004-0769-5","volume":"60","author":"E Dailly","year":"2004","unstructured":"Dailly E, Billaud E, Reliquet V, Breurec S, Perre P, Leautez S, Jolliet P, Bourin M, Raffi F (2004) No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 60(5):343\u2013348","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"481_CR44","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","volume":"27","author":"DA Erickson","year":"1999","unstructured":"Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27(12):1488\u20131495","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-008-0481-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0481-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:37:06Z","timestamp":1738345026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-008-0481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,27]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0481-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2008,8,27]]},"assertion":[{"value":"1 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"71"}}